Inactive Instrument

Sichuan Languang Development Co., Ltd. Stock price

Equities

600466

CNE0000017B4

Real Estate Development & Operations

Dynamic Chart
Sichuan Languang Development Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Sichuan Languang Development Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Languang Development to Delist From Shanghai Bourse MT
Sichuan Languang Development Co., Ltd.(SHSE:600466) dropped from Shanghai Stock Exchange Composite Index CI
Sichuan Languang Development Co., Ltd.(SHSE:600466) dropped from Shanghai Stock Exchange A Share Index CI
Sichuan Languang Defaults on 510 Million Yuan More Debts MT
Sichuan Languang Development Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
US Jobs Outlook Limits Upside in Asian Stock Markets MT
Sichuan Languang Development Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
An unknown buyer acquired a 5.10% stake in Sichuan Languang Development Co., Ltd. from Century Ginwa Co., Ltd. CI
Sichuan Languang Development Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Over Half of Chinese Property Developers Warn of Losses in H1 MT
Chinese Shares End Mixed; Languang Development Falls 5% as Controlling Shareholder Cuts Stake MT
Sichuan Languang Development Parent Cuts Stake to 35%; Shares Fall 4% MT
Sichuan Languang Development Co., Ltd.(XSSC:600466) dropped from S&P Global BMI Index CI
More news
SICHUAN LANGUANG DEVELOPMENT CO., LTD. mainly operates business through real estate development and operation, modern service industry, 3 dimension (3D) bio-printing and medical segment. The Real Sstate Development & Operation segment has more than 100 development projects in nearly 20 cities in China. The Modern Service Industry segment provides property service based modern services through the subsidiary, Sichuan JUSTBON Asset Management Group Co., Ltd. The 3D Bio-printing segment is involved in the application of 3D bio-printing technology through the subsidiary, Sichuan Revotek Bio-technology Co., Ltd. The Medical segment is involved in the research and development, production and sales of medicine and medical instruments through the subsidiary, Chengdu Dikang Pharmaceutical Co., Ltd.
More about the company
  1. Stock
  2. Equities
  3. Stock Sichuan Languang Development Co., Ltd. - Shanghai S.E.